Cryptogenic Stroke
NEJM 374:2065-2074, Saver, J.L., 2016
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Outcome of Acute Stroke Patients Without Visible Occlusion on Early Arteriography
Stroke 35:1135-1140, Arnold,M.,et al, 2004
Surgical Closure of Patent Foramen Ovale in Cryptogenic Stroke Patients
Stroke 28:2376-2381, Homma,S.,et al, 1997
The Effect of Multiple Neuroimaging Studies on Classification, Treatment and Outcome of Acute Ischemic Stroke
Ann Int Med 124:21-26, Salerno,S.M.,et al, 1996
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Recurrent Thromboembolic Events after Ischemic Stroke in Patients with Cancer
Neurol 83:26-33, Navi, B.B.,et al, 2014
Patent Foramen Ovale and Cryptogenic Stroke
Stroke 44:2676-2678, Furlan, A.J. and Jauss, M., 2013
Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005
Practice Parameter: Recurrent Stroke with Patent Foramen Ovale and Atrial Septal Aneurysm
Neurol 62:1042-1050, Messe,S.R.,et al, 2004